Impact of tumor growth rate during preceding treatment on tumor response to nivolumab or irinotecan in advanced gastric cancer

Kang, 2017, Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double blind, placebo-controlled, phase 3 trial, Lancet, 390, 2461, 10.1016/S0140-6736(17)31827-5 Fuchs, 2018, Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer, JAMA Oncol, 4, e180013, 10.1001/jamaoncol.2018.0013 Hironaka, 2013, Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial, J Clin Oncol, 31, 4438, 10.1200/JCO.2012.48.5805 Bang, 2018, Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300, Ann Oncol, 29, 2052, 10.1093/annonc/mdy264 2021, Japanese gastric cancer treatment guidelines 2018 (5th edition), Gastric Cancer, 24, 1, 10.1007/s10120-020-01042-y Masuishi, 2019, Impact of tumour growth rate during preceding treatment on tumour response to regorafenib or trifluridine/tipiracil in refractory metastatic colorectal cancer, ESMO Open, 4, e000584, 10.1136/esmoopen-2019-000584 Kanda, 2013, Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics, Bone Marrow Transplant, 48, 452, 10.1038/bmt.2012.244 Joseph, 2018, Baseline tumor size is an independent prognostic factor for overall survival in patients with melanoma treated with pembrolizumab, Clin Cancer Res, 24, 4960, 10.1158/1078-0432.CCR-17-2386 Nosrati, 2017, Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy, Br J Cancer, 116, 1141, 10.1038/bjc.2017.70 Weide, 2016, Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab, Clin Cancer Res, 22, 5487, 10.1158/1078-0432.CCR-16-0127 Suzuki, 2020, Effect of tumor burden and growth rate on treatment outcomes of nivolumab in head and neck cancer, Int J Clin Oncol, 25, 1270, 10.1007/s10147-020-01669-y Nishimura, 2017, Irinotecan monotherapy as third-line treatment for advanced gastric cancer refractory to fluoropyrimidines, platinum, and taxanes, Gastric Cancer, 20, 655, 10.1007/s10120-016-0670-9 Shitara, 2018, Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet Oncol, 19, 1437, 10.1016/S1470-2045(18)30739-3